• Je něco špatně v tomto záznamu ?

Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 Study

A. Oriol, R. Hájek, I. Spicka, I. Sandhu, YC. Cohen, ME. Gatt, J. Mariz, M. Cavo, J. Berdeja, K. Jin, M. Bar, P. Das, R. Motte-Mohs, Y. Wang, D. Perumal, LJ. Costa

. 2024 ; 24 (10) : 703-714. [pub] 20240519

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, klinické zkoušky, fáze III, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc24018812

BACKGROUND: Preclinical studies suggest that combining nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor, with pomalidomide/dexamethasone (Pd) with or without elotuzumab, an antisignaling lymphocytic activation molecule F7 monoclonal antibody, may improve multiple myeloma (MM) treatment efficacy. PATIENTS AND METHODS: The phase 3 CheckMate 602 study (NCT02726581) assessed the efficacy and safety of nivolumab plus pomalidomide/dexamethasone (NPd) and NPd plus elotuzumab (NE-Pd). Eligible patients (aged ≥ 18 years) had measurable MM after ≥ 2 prior lines of therapy, that included an immunomodulatory drug (IMiD) and proteasome inhibitor (PI), each for ≥ 2 consecutive cycles, alone or combined, and were refractory to their last line of therapy. Patients were randomized 3:3:1 to receive NPd, Pd, or NE-Pd. The primary endpoint was progression-free survival (PFS); overall response rate (ORR) was a key secondary endpoint. RESULTS: At a median follow-up of 16.8 months, PFS was similar between treatment arms (Pd, 7.3 months [95% CI, 6.5-8.4]; NPd, 8.4 months [95% CI, 5.8-12.1]; NE-Pd, 6.3 months [95% CI, 2.4-11.1]). ORR was similar in the Pd (55%), NPd (48%), and NE-Pd (42%) arms. Nivolumab-containing arms were associated with a less favorable safety profile versus Pd, including a higher rate of thrombocytopenia (NPd, 25.0%; NE-Pd, 16.7%; Pd, 15.7%), any-grade immune-mediated adverse events (NPd, 13.9%; NE-Pd, 16.7%; Pd, 2.9%), and adverse events leading to discontinuation (NPd, 25.0%; NE-Pd, 33.3%; Pd, 18.6%). No new safety signals were identified. CONCLUSION: CheckMate 602 did not demonstrate clinical benefit of nivolumab (+/- elotuzumab) plus Pd versus Pd for patients with relapsed/refractory MM (RRMM).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24018812
003      
CZ-PrNML
005      
20241024111314.0
007      
ta
008      
241015s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.clml.2024.05.014 $2 doi
035    __
$a (PubMed)38849283
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Oriol, Albert $u Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain. Electronic address: aoriol@iconcologia.net
245    10
$a Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 Study / $c A. Oriol, R. Hájek, I. Spicka, I. Sandhu, YC. Cohen, ME. Gatt, J. Mariz, M. Cavo, J. Berdeja, K. Jin, M. Bar, P. Das, R. Motte-Mohs, Y. Wang, D. Perumal, LJ. Costa
520    9_
$a BACKGROUND: Preclinical studies suggest that combining nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor, with pomalidomide/dexamethasone (Pd) with or without elotuzumab, an antisignaling lymphocytic activation molecule F7 monoclonal antibody, may improve multiple myeloma (MM) treatment efficacy. PATIENTS AND METHODS: The phase 3 CheckMate 602 study (NCT02726581) assessed the efficacy and safety of nivolumab plus pomalidomide/dexamethasone (NPd) and NPd plus elotuzumab (NE-Pd). Eligible patients (aged ≥ 18 years) had measurable MM after ≥ 2 prior lines of therapy, that included an immunomodulatory drug (IMiD) and proteasome inhibitor (PI), each for ≥ 2 consecutive cycles, alone or combined, and were refractory to their last line of therapy. Patients were randomized 3:3:1 to receive NPd, Pd, or NE-Pd. The primary endpoint was progression-free survival (PFS); overall response rate (ORR) was a key secondary endpoint. RESULTS: At a median follow-up of 16.8 months, PFS was similar between treatment arms (Pd, 7.3 months [95% CI, 6.5-8.4]; NPd, 8.4 months [95% CI, 5.8-12.1]; NE-Pd, 6.3 months [95% CI, 2.4-11.1]). ORR was similar in the Pd (55%), NPd (48%), and NE-Pd (42%) arms. Nivolumab-containing arms were associated with a less favorable safety profile versus Pd, including a higher rate of thrombocytopenia (NPd, 25.0%; NE-Pd, 16.7%; Pd, 15.7%), any-grade immune-mediated adverse events (NPd, 13.9%; NE-Pd, 16.7%; Pd, 2.9%), and adverse events leading to discontinuation (NPd, 25.0%; NE-Pd, 33.3%; Pd, 18.6%). No new safety signals were identified. CONCLUSION: CheckMate 602 did not demonstrate clinical benefit of nivolumab (+/- elotuzumab) plus Pd versus Pd for patients with relapsed/refractory MM (RRMM).
650    _2
$a lidé $7 D006801
650    12
$a mnohočetný myelom $x farmakoterapie $x mortalita $7 D009101
650    12
$a nivolumab $x terapeutické užití $x farmakologie $x aplikace a dávkování $7 D000077594
650    _2
$a mužské pohlaví $7 D008297
650    12
$a humanizované monoklonální protilátky $x terapeutické užití $x aplikace a dávkování $x farmakologie $7 D061067
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    12
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $x farmakologie $7 D000971
650    _2
$a senioři $7 D000368
650    12
$a thalidomid $x analogy a deriváty $x terapeutické užití $x farmakologie $x aplikace a dávkování $7 D013792
650    _2
$a dospělí $7 D000328
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a lokální recidiva nádoru $x farmakoterapie $7 D009364
655    _2
$a časopisecké články $7 D016428
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Hájek, Roman $u University Hospital Ostrava and Faculty of Medicine, University of Ostrava 17, Ostrava, Czech Republic
700    1_
$a Spicka, Ivan $u Charles University and General Hospital in Prague, Czech Republic
700    1_
$a Sandhu, Irwindeep $u University of Alberta, Edmonton, Alberta, Canada
700    1_
$a Cohen, Yael C $u Tel-Aviv Sourasky Medical Center and Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel
700    1_
$a Gatt, Moshe E $u Hadassah University Medical Center, Hebrew University of Jerusalem, Israel
700    1_
$a Mariz, José $u Instituto Portugues de Oncologia, Porto, Portugal
700    1_
$a Cavo, Michele $u IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", and Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy
700    1_
$a Berdeja, Jesús $u Sarah Cannon Research Institute, Nashville, TN
700    1_
$a Jin, Kexin $u Bristol Myers Squibb, Summit, NJ
700    1_
$a Bar, Merav $u Bristol Myers Squibb, Summit, NJ
700    1_
$a Das, Prianka $u Bristol Myers Squibb, Summit, NJ
700    1_
$a Motte-Mohs, Ross La $u Bristol Myers Squibb, Summit, NJ
700    1_
$a Wang, Yu $u Bristol Myers Squibb, Princeton, NJ
700    1_
$a Perumal, Deepak $u Bristol Myers Squibb, Princeton, NJ
700    1_
$a Costa, Luciano J $u Division of Hematology and Oncology, University of Alabama, Birmingham, AL
773    0_
$w MED00180199 $t Clinical lymphoma, myeloma & leukemia $x 2152-2669 $g Roč. 24, č. 10 (2024), s. 703-714
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38849283 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024111308 $b ABA008
999    __
$a ok $b bmc $g 2201582 $s 1230785
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 24 $c 10 $d 703-714 $e 20240519 $i 2152-2669 $m Clinical lymphoma, myeloma & leukemia $n Clin Lymphoma Myeloma Leuk $x MED00180199
LZP    __
$a Pubmed-20241015

Najít záznam

Citační ukazatele

Možnosti archivace